JointHealth™ express   October 26, 2013

Good news in Quebec

Certolizumab Pegol (Cimzia®) for the treatment of rheumatoid arthritis approved in Quebec.

As of October 1st, certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis has been listed for coverage on Quebec’s drug formulary. Click here to view the detailed medication criteria.

Now there are more treatment options available in Quebec, which is important because every patient responds differently to disease suppressing or modifying medications.

Certolizumab pegol is an anti-TNF medication taken by subcutaneous injection every two weeks. To learn if certolizumab pegol or other rheumatoid arthritis treatment may be helpful to you, please speak to your rheumatologist or other healthcare provider who is helping you to manager your disease.

Click here to view the most up-to-date version of ACE's Report Card on provincial formulary reimbursement listings for biologic response modifiers.